Janssen (J&J) Reports Results of Erleada (apalutamide) in P-III TITAN Study for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) #ASCO2019

Janssen (J&J) Reports Results of Erleada (apalutamide) in P-III TITAN Study for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) #ASCO2019

Shots:

  • The P-III TITAN study involves assessing of Erleada + Androgen Deprivation Therapy (ADT) vs PBO + ADT in 1050 patients in ratio 1:1 with mCSPC across 23 countries
  • The P-III study results: @22.7 mos. OS (82% vs 74%); PSA (68% vs 29%); 52% reduction in risk of radiographic progression; 61% reduction in time to cytotoxic CT; 34% reduction in PFS2
  • Erleada (apalutamide) is an androgen receptor (AR) inhibitor and has received FDA approval for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) on 14 Feb,2018. The results of P-III TITAN study will accelerate the approval of Erleada for mCSPC

Click Here, Click here to read full press release/ article | Ref: Janssen | Image: Twitter